These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 27513300)
81. A review on ROCK-II inhibitors: From molecular modelling to synthesis. Shah S; Savjani J Bioorg Med Chem Lett; 2016 May; 26(10):2383-2391. PubMed ID: 27080184 [TBL] [Abstract][Full Text] [Related]
82. Cytokine enhancement of immunogenicity in chronic myeloid leukaemia. Coleman S; Throp D; Fisher J; Bailey-Wood R; Lim SH Leukemia; 1997 Dec; 11(12):2055-9. PubMed ID: 9447820 [TBL] [Abstract][Full Text] [Related]
83. Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity. Choudhury A; Toubert A; Sutaria S; Charron D; Champlin RE; Claxton DF Crit Rev Immunol; 1998; 18(1-2):121-31. PubMed ID: 9419454 [TBL] [Abstract][Full Text] [Related]
85. HLA antigens in Sicilian patients affected by chronic myelogenous leukaemia. Caruso C; Lo Campo P; Botindari C; Modica MA J Immunogenet; 1987 Dec; 14(6):295-9. PubMed ID: 3509755 [TBL] [Abstract][Full Text] [Related]
86. Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. Giallongo C; Parrinello N; Tibullo D; La Cava P; Romano A; Chiarenza A; Barbagallo I; Palumbo GA; Stagno F; Vigneri P; Di Raimondo F PLoS One; 2014; 9(7):e101848. PubMed ID: 25014230 [TBL] [Abstract][Full Text] [Related]
87. The chronic myeloid leukaemia story in the United Kingdom since 1960. Clark RE Br J Haematol; 2020 Nov; 191(4):521-526. PubMed ID: 33190253 [TBL] [Abstract][Full Text] [Related]
88. Glycolipid iGb3 feedback amplifies innate immune responses via CD1d reverse signaling. Liu X; Zhang P; Zhang Y; Wang Z; Xu S; Li Y; Huai W; Zhou Q; Chen X; Chen X; Li N; Wang P; Li Y; Cao X Cell Res; 2019 Jan; 29(1):42-53. PubMed ID: 30514903 [TBL] [Abstract][Full Text] [Related]
95. PKM2 Is Required to Activate Myeloid Dendritic Cells from Patients with Severe Aplastic Anemia. Liu C; Zheng M; Wang T; Jiang H; Fu R; Wang H; Ding K; Zhou Q; Shao Z Oxid Med Cell Longev; 2018; 2018():1364165. PubMed ID: 29636835 [TBL] [Abstract][Full Text] [Related]
96. [Immunosuppressive action of polyamines in patients with chronic myeloid leukemia]. Shardakov VI; Dem'ianova VT; Kopaneva TG Gematol Transfuziol; 1994; 39(1):9-11. PubMed ID: 8188035 [TBL] [Abstract][Full Text] [Related]
97. A clinical appraisal of chronic myeloid leukaemia (CML)-related death and CML-specific death-Are they synonymous? Eşkazan AE Int J Clin Pract; 2021 Jun; 75(6):e14217. PubMed ID: 33998756 [No Abstract] [Full Text] [Related]
98. Chronic myeloid leukaemia after chemoradiotherapy for solid malignancies. Baysal M; Ulutas G; Gokyer A; Umit E; Atli EI; Kirkizlar O; Gürkan H; Demir AM Natl Med J India; 2020; 33(6):347-348. PubMed ID: 34341212 [TBL] [Abstract][Full Text] [Related]
99. Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells. Dockry É; O'Leary S; Gleeson LE; Lyons J; Keane J; Gray SG; Doherty DG Oncoimmunology; 2018; 7(6):e1428156. PubMed ID: 29872551 [TBL] [Abstract][Full Text] [Related]
100. Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity. Pinto-Fernandez A; Salio M; Partridge T; Chen J; Vere G; Greenwood H; Olie CS; Damianou A; Scott HC; Pegg HJ; Chiarenza A; Díaz-Saez L; Smith P; Gonzalez-Lopez C; Patel B; Anderton E; Jones N; Hammonds TR; Huber K; Muschel R; Borrow P; Cerundolo V; Kessler BM Br J Cancer; 2021 Feb; 124(4):817-830. PubMed ID: 33214684 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]